A mark of experience1
The first and only oral JAKi approved for the treatment of RA, UC and PsA1-3
XELJANZ® has been prescribed to >260,000 patients across indications globally and has up to 9.5 years of long-term safety data in RA, up to 6.8 years in UC and up to 3 years in PsA4-8
JAKis are recommended as a treatment option for RA in the EULAR recommendations 2019 update and in the 2015 ACR guidelines9,10
They are recommended as a treatment option for PsA in the EULAR recommendations 2019 update11
ACR, American College of Rheumatology; EULAR, European Alliance of Associations for Rheumatology; JAKi, Janus kinase inhibitor; PsA, psoriatic arthritis; RA, rheumatoid arthritis; UC, ulcerative colitis.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022